Overview

This trial is active, not recruiting.

Conditions pseudohypoparathyroidism type 1a, albright hereditary osteodystrophy
Sponsor Children's Hospital of Philadelphia
Start date June 2011
End date September 2015
Trial size 519 participants
Trial identifier NCT01398774, 11-007972

Summary

The investigators would like to learn more about the metabolic consequences of pseudohypoparathyroidism type 1a in children, adolescents and adults with this condition. People with pseudohypoparathyroidism 1a are at risk for development of obesity. To better understand the cause of overweight or obesity, investigators are measuring body composition and resting energy expenditure (REE), which is the amount of calories burned while completely at rest. The investigators also want to determine the amount of body fat.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional

Primary Outcomes

Measure
Resting Energy Expenditure
time frame: 30 minutes

Secondary Outcomes

Measure
Characterize body composition in patients with PHP1a.
time frame: 12 months

Eligibility Criteria

Male or female participants from 5 years up to 45 years old.

Inclusion Criteria: - Diagnosis of pseudohypoparathyroidism 1a - Any body weight Exclusion Criteria: - Absence of above diagnosis

Additional Information

Official title Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study
Principal investigator Michael A Levine, M.D.
Description Pseudohypoparathyroidism 1a (PHP1a) is a disorder that is associated with many endocrine problems. People with PHP1a are at risk for the development of obesity. The objective of the study will help determine if obesity is related to abnormalities energy expenditure, meaning that people with PHP1a may not burn as many calories while at rest as those without the disorder. In order to further evaluate obesity in PHP1a, investigators are planning to measure resting energy expenditure (REE), which is the amount of calories burned while completely at rest. Investigators will also evaluate body composition by looking at measures of growth and development and determining the amount of body fat using dual energy x-ray absorptiometry (DXA) as well as blood and urine biologic markers of obesity. The investigators plan to evaluate people with PHP1a at all weights.
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Children's Hospital of Philadelphia.